Waters Corp: An Analytical Instrument Leader at an Inflection Point, Leveraging Strategic Transformation for the Next Phase of Growth.
Overview
Waters Corp is a premier provider of specialty analytical instruments, highlighted by expertise in chromatography and mass spectrometry. With global reach and entrenched relationships in key regulated end-markets—pharmaceuticals/biotech (accounting for nearly 60% of sales), industry, and government/academic labs—the firm enjoys resilient demand and outstanding margins. Its premium performance products, extensive service ecosystem, and recurring revenue streams create a robust, defensible business model. Recent initiatives center on reinvigorating growth via innovation and product upgrades, and a bold, transformative transaction: acquiring BD’s Biosciences & Diagnostic Solutions business. This deal will double Waters’ addressable market, diversify its technology base, and sharply elevate recurring revenues, with pro-forma sales anticipated to top $6.5B in 2025 and over 70% of revenues recurring. Waters is thus poised at a pivotal juncture—marrying a proven, premium-value business with ambitious growth opportunities.